ArticleMolecular neurobiology2025
Spirilloxanthin from Verbesina encelioides Flower Extract has Neuroprotective Benefits in Scopolamine-Induced Memory Impaired Rats that Resemble Alzheimer's Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical diversity and therapeutic potential ofFrontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal degeneration is a widespread complication associated with ageing, with Alzheimer's disease (AD) being one of the most prevalent neurodegenerative disorders. AD is marked by limited treatment options and significant side effects, prompting growing interest in natural compounds for their therapeutic potential. This study evaluates the neuroprotective effects of spirilloxanthin, a major bioactive compound identified in the flower extract of Verbesina encelioides (VFE), against scopolamine-induced neurobehavioral impairments in a rat model of AD. Gas chromatography-mass spectrometry (GC-MS) analysis confirmed spirilloxanthin as a key constituent of the extract. The administration of purified VFE to rats exhibiting AD-like symptoms significantly improved learning and memory. Biochemical analyses further revealed enhanced cognitive performance and a notable reduction in free radical production, indicating mitigation of oxidative stress. Complementary in silico molecular docking studies were performed to examine the interactions between spirilloxanthin and gingkolide A with acetylcholinesterase, shedding light on their potential mechanisms of action. In summary, the study demonstrates that VFE improves cognitive function and counteracts scopolamine-induced deficits, highlighting V. encelioides as a promising natural therapeutic candidate for neurodegenerative conditions such as dementia and Alzheimer's disease.
Indexed as
Identifiers
40437285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.